查看完整行情页>>

|

货币单位:美元(USD)

Puma Biotechnology, Inc. (pbyi)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Michael Patrick Miller Michael Patrick Miller is on the board of The Leukemia & Lymphoma Society, Inc., Puma Biotechnology, Inc. and Zane Beadles Parade Foundation. In his past career Mr. Miller occupied the position of Executive Vice President-Commercial at Jazz Pharmaceuticals Plc, Chief Commercial Officer & Senior Vice President at VIVUS, Inc., Vice President-Commercial Operations at Cellegy Pharmaceuticals, Inc., Vice President of ALZA Corp., Senior Vice President-Sales & Marketing of Connetics Corp. and Vice President-Sales & Marketing for Genentech, Inc. Mr. Miller received an undergraduate degree from the University of San Francisco and an MBA from San Francisco State University.
Jay M. Moyes Jay M. Moyes is on the board of Puma Biotechnology, Inc., BioCardia, Inc. and Achieve Life Sciences, Inc. and Managing Member at Drayton Investments LLC and Member of Utah Association of Certified Public Accountants. In the past Mr. Moyes occupied the position of Chief Financial Officer for CareDx, Inc., Chief Financial Officer & Director at SINTX Technologies, Inc., Chief Financial Officer at Myriad Genetics, Inc., Chief Financial Officer & Vice President-Finance at Genmarks, Inc. and Senior Manager at KPMG LLP. Mr. Moyes received an MBA from the University of Utah and an undergraduate degree from Weber State University.
Frank E. Zavrl Frank E. Zavrl is on the board of Puma Biotechnology, Inc. and EIP Pharma, Inc. In the past Mr. Zavrl was Portfolio Manager at Merlin Biomed Group LLC, Equity Analyst at Adage Capital Management LP and Analyst at Zurich Scudder Investments, Inc. Frank E. Zavrl received an undergraduate degree from the University of California, Berkeley and an MBA from Tuck School of Business at Dartmouth.
Alan H. Auerbach Alan H. Auerbach founded Cougar Biotechnology, Inc. and Puma Biotechnology, Inc. Currently, he is Chairman, President, CEO & Secretary at Puma Biotechnology, Inc. Mr. Auerbach previously occupied the position of Vice President & Research Analyst at Seidler Cos., Inc., Chairman, President & Chief Executive Officer for Innovative Acquisitions Corp., President, Chief Executive Officer & Director at Cougar Biotechnology, Inc., Vice President & Senior Research Analyst at Wells Fargo Securities (Old) and Vice President & Senior Research Analyst at Diagnostic Products Corp. Mr. Auerbach received an undergraduate degree from Boston University and a graduate degree from the University of Southern California.
Mariann Ohanesian Mariann Ohanesian holds the position of Senior Director-Investor Relations at Puma Biotechnology, Inc. and Director-Investor Relations for Janssen Oncology, Inc.
Richard Paul Bryce Presently, Richard Paul Bryce occupies the position of Chief Medical & Scientific Officer at Puma Biotechnology, Inc. Dr. Bryce is also Member of American Society of Hematology, Member of European Society for Medical Oncology, Member of Royal College of General Practitioners, Member of The Royal College of Physicians and Member of American Society of Clinical Oncology. In the past Dr. Bryce occupied the position of Executive Vice President-Medical Affairs at Ergomed Plc, Senior Medical Director at ICON Clinical Research, Inc. and Senior Medical Director at Onyx Pharmaceuticals, Inc. He received a doctorate and an undergraduate degree from The University of Edinburgh.
Adrian M. Senderowicz Adrian M. Senderowicz is on the board of Puma Biotechnology, Inc. In his past career Dr. Senderowicz occupied the position of Chief Medical Officer & Senior Vice President at Constellation Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President of Daré Bioscience, Inc. and Chief Medical Officer & Senior Vice President at Cerulean Pharma, Inc. (a subsidiary of Daré Bioscience, Inc.), Vice President-Global Regulatory Oncology at Sanofi, Senior Medical Director-Oncology Division at AstraZeneca Plc, Chief Medical Officer & SVP-Regulatory Affairs at Ignyta, Inc., Chief Medical Officer & VP-Medical Development at Tokai Pharmaceuticals, Inc., Head-Prostate Cancer Clinic at National Institutes of Health and Clinical Team Leader-Oncology Division at US Food & Drug Administration. Adrian M. Senderowicz received a doctorate from Universidad de Buenos Aires.
Troy E. Wilson Founder of 5 different companies, which include: Kura Oncology, Inc., Avidity Biosciences, Inc. and Intellikine LLC, Troy E. Wilson is an entrepreneur and businessperson who has been at the head of 8 different companies and presently is Chairman, President & Chief Executive Officer for Kura Oncology, Inc. (which he founded in 2014) and Executive Chairman of Avidity Biosciences, Inc. (which he founded in 2012). He is also on the board of Puma Biotechnology, Inc. Troy E. Wilson previously occupied the position of President, Chief Executive Officer & Director at Wellspring Biosciences LLC, President & Chief Executive Officer for Araxes Pharma LLC, President at Wildcat Discovery Technologies, Inc. (he founded the company), Chief Business Officer at Ambrx, Inc. (he founded the company in 2003), Founding Partner of Presidio Partners, Chairman, President & Chief Executive Officer for Zeta Acquisition Corp. III, President, Chief Executive Officer & Director at Intellikine LLC (he founded the company in 2007), Chief Executive Officer of Takeda Pharmaceuticals U.S.A., Inc. and Vice President-Business Development of Novartis Institute for Functional Genomics, Inc. Troy E. Wilson received a doctorate and an undergraduate degree from the University of California, Berkeley and a graduate degree from New York University.
Hugh O'Dowd Hugh O'Dowd is on the board of Puma Biotechnology, Inc. In his past career he held the position of President, Chief Executive Officer & Director at BioNTech US, Inc., President & General Manager at Novartis Ireland Ltd., President & General Manager at Novartis UK Ltd., General Manager at Novartis International Pharmaceutical Ltd. and Chief Commercial Officer & Head-Global Strategy at Novartis Oncology, Inc. He received an undergraduate degree from Loyola University of Chicago and an MBA from Kellstadt Graduate School of Business.
Douglas Hunt Douglas Hunt occupies the position of SVP-Regulatory Affairs & Medical Writing at Puma Biotechnology, Inc. In his past career Mr. Hunt was Executive Director-Therapeutic Area at Amgen, Inc., VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. and Vice President-Global Regulatory Affairs at Baxter Healthcare Corp. Douglas Hunt received an undergraduate degree from the University of Portsmouth.
Maximo F. Nougues Presently, Maximo F. Nougues holds the position of Chief Financial Officer for Puma Biotechnology, Inc. Mr. Nougues previously occupied the position of Chief Financial Officer-North America Region at Getinge AB and Chief Financial Officer & Regional VP-Finance at MAQUET Cardiovascular LLC (a subsidiary of Getinge AB). Maximo F. Nougues received a graduate degree from Universidad Del Norte Santo Tomas De Aquino and an MBA from Mclaren School of Business.
Ann Calby Miller Ann Calby Miller is on the board of Inovio Pharmaceuticals, Inc. and Puma Biotechnology, Inc. Dr. Miller previously held the position of Senior Vice President-Pharmaceutical Services at Eisai Co., Ltd. and Vice President-Marketing of Sanofi SA. He received an undergraduate degree from Duke University and a doctorate from Duke University School of Medicine.
Jeffrey Ludwig Jeffrey Ludwig is Chief Commercial Officer for Puma Biotechnology, Inc. In the past Mr. Ludwig held the position of Vice President-Oncology Sales at Astellas Pharma, Inc. and Vice President-Oncology Sales at Amgen, Inc. He received an undergraduate degree from Arizona State University.